Scott + Scott, LLC Files Securities Lawsuit Against Biovail Corporation

COLCHESTER, Conn., Nov. 14 /PRNewswire/ -- Scott + Scott, LLC (scottlaw@scott-scott.com), a law firm with offices in Connecticut and California, announced that it has filed a securities class-action on behalf of all persons who purchased the common shares of Biovail Corporation (NYSE: BVF - News; TSX: BVF - News; "Biovail" or the "Company") between May 17, 2002 and October 30, 2003 (the "Class Period" or the "Class") for violations of the federal securities laws. Biovail's common shares are traded on the New York Stock Exchange and on the Toronto Stock Exchange.

Plaintiff shareholder is seeking to pursue remedies under the Securities Exchange Act of 1934 (the "Exchange Act"). A copy of the complaint filed in this action on behalf of investors is available from the Court or can be obtained by calling Scott + Scott, LLC at 800/404-7770, e-mailing the firm at rothstein@aol.com or drscott@scott-scott.com, or going to the firm's website (http://www.scott-scott.com/) and clicking on "IN THE NEWS."

While Biovail has called this lawsuit "frivolous," the Canadian drugmaker has been criticized for not properly estimating inventories of its drugs; low revenue from its generic brand of Prilosec and excess inventory of heart drug Cardizem CD. Chief Executive Eugene Melnyk has been criticized for the purchase of a company plane by an entity he controlled, the use of Barbados as a tax shelter for Biovail, a doctor compensation program that pays doctors for using Cardizem LA and acquisitions that led to confusing accounting.

The U.S. Department of Health and Human Services is currently investigating the propriety of the physician compensation program.

The Complaint alleges that Biovail and certain of its officers and directors made materially false and misleading statements during the Class Period. Specifically, Defendants made material misrepresentations concerning Biovail's financial results and business by improperly reporting revenue and earnings attributable to sales. Plaintiff further alleges that these material misrepresentations artificially inflated the price of Biovail's common shares, which traded as high as $50.30 on the New York Stock Exchange and as high as CD $67.75 on the Toronto Stock Exchange during the Class Period.The stock opened today in New York at $24.50.

Scott + Scott, LLC is engaged in the representation of funds, foundations, endowments, institutions, pension funds, individuals, and other entities throughout the world in securities, antitrust and other complex class and non- class action litigation. The firm maintains the highest standards for client satisfaction and communication. The firm's attorneys litigate in both state and federal courts throughout the nation. The firm has been appointed lead counsel in cases nationwide, including the ongoing ImClone Securities Litigation. The firm also recently settled cases against Mattel and Emulex in which it was lead counsel. Scott + Scott, LLC issues this release in accordance with the applicable federal securities laws. If you wish to discuss this action, have any questions concerning this notice, your rights with respect to this matter or any other securities fraud matter please contact Neil Rothstein Esq.,nrothstein@aol.com, or David Scott Esq., drscott@scott- scott.com, Scott + Scott, LLC, 108 Norwich Avenue, Colchester, Connecticut 06415 at 800/404-7770 (fax: 860/537-4432).

Scott + Scott, LLC

CONTACT: Neil Rothstein Esq., nrothstein@aol.com, or David Scott Esq.,drscott@scott-scott.com, of Scott + Scott, LLC, +1-800-404-7770

Back to news